Aldagen, Inc. (ALDH) Announces Clinical Data for ALD-201 for Ischemic Heart Failure Presented at AHA
11/18/2009 10:01:47 AM
More...
|
Phase 1/2 Results for Aldagen, Inc. (ALDH)'s ALD-301 Critical Limb Ischemia Clinical Study Presented at American Heart Association
11/16/2009 10:51:47 AM
More...
|
Clinical Data on Aldagen, Inc. (ALDH)'s Cardiovascular Therapies to Be Presented at the American Heart Association Scientific Sessions 2009
11/10/2009 10:22:31 AM
More...
|
Aldagen, Inc. (ALDH) Files for $80.5 Million IPO
10/29/2009 11:02:45 AM
More...
|
Aldagen, Inc. Announces Participation in Rodman & Renshaw 11th Annual Healthcare Conference
9/8/2009 1:26:47 PM
More...
|
Aldagen, Inc. Reaches Agreement With FDA on a Special Protocol Assessment (SPA) for Phase 3 Trial of ALD-301 for Critical Limb Ischemia
8/5/2009 10:56:41 AM
More...
|
Aldagen, Inc. Announces Review Article on Potential of Its Adult Stem Cell Therapies for Cardiovascular Diseases
7/29/2009 11:15:18 AM
More...
|
Aldagen, Inc. Announces Participation in Breakout Sessions at 2009 Biotechnology Industry Organization (BIO) International Convention
5/18/2009 12:23:02 PM
More...
|
Aldagen, Inc. Announces Positive Phase 1/2 Results for Critical Limb Ischemia Stem Cell Therapy ALD-301
11/20/2008 8:18:05 AM
More...
|
Aldagen, Inc. And University of California, Davis (UCD) Form Collaboration Related to Neural Diseases
11/6/2008 8:39:23 AM
More...
|
|